OBJECTIVE: Incidence of venous thromboembolism (VTE) and need for thromboprophylaxis in urologic surgery have received little attention since only one randomised study has addressed this issue in the last 20 yr. The present prospective observational study evaluated incidence and risk factors for clinically overt VTE in a wide spectrum of consecutive patients undergoing surgery for cancer and compared findings in urologic patients with those in patients undergoing general or gynaecologic surgery. METHODS: Patients having cancer surgery (general surgery, gynaecology, urology) were assessed for clinically overt VTE occurring up to 30+/-5 d after intervention or more if the hospital stay was longer. All suspected VTE events were evaluated by an external independent Adjudication Committee. RESULTS: A total of 2373 patients, 1238 (52%) undergoing general surgery, 685 (29%) urologic, and 450 (19%) gynaecologic surgery were evaluated. In urologic patients, most procedures (61%) were endoscopic, with bladder and prostate cancer being the most frequent tumours. In-hospital thromboprophylaxis was given to 71.7% of patients, whereas 32.5% received prophylaxis after discharge. The incidence of VTE in urologic patients was lower (0.87%) than that in general surgery and gynaecologic patients (2.8% and 2.0%, respectively). VTE consisted of three cases of nonfatal and three cases of fatal pulmonary embolism (PE). In four of the six cases, VTE occurred during prophylaxis. CONCLUSIONS: VTE still represents a severe complication and remains the most common cause of death after urologic cancer surgery. Efforts should be made to optimise prophylactic measures to further reduce such risk.
OBJECTIVE: Incidence of venous thromboembolism (VTE) and need for thromboprophylaxis in urologic surgery have received little attention since only one randomised study has addressed this issue in the last 20 yr. The present prospective observational study evaluated incidence and risk factors for clinically overt VTE in a wide spectrum of consecutive patients undergoing surgery for cancer and compared findings in urologic patients with those in patients undergoing general or gynaecologic surgery. METHODS:Patients having cancer surgery (general surgery, gynaecology, urology) were assessed for clinically overt VTE occurring up to 30+/-5 d after intervention or more if the hospital stay was longer. All suspected VTE events were evaluated by an external independent Adjudication Committee. RESULTS: A total of 2373 patients, 1238 (52%) undergoing general surgery, 685 (29%) urologic, and 450 (19%) gynaecologic surgery were evaluated. In urologic patients, most procedures (61%) were endoscopic, with bladder and prostate cancer being the most frequent tumours. In-hospital thromboprophylaxis was given to 71.7% of patients, whereas 32.5% received prophylaxis after discharge. The incidence of VTE in urologic patients was lower (0.87%) than that in general surgery and gynaecologic patients (2.8% and 2.0%, respectively). VTE consisted of three cases of nonfatal and three cases of fatal pulmonary embolism (PE). In four of the six cases, VTE occurred during prophylaxis. CONCLUSIONS:VTE still represents a severe complication and remains the most common cause of death after urologic cancer surgery. Efforts should be made to optimise prophylactic measures to further reduce such risk.
Authors: Wojciech Michalski; Grazyna Poniatowska; Joanna Jonska-Gmyrek; Jakub Kucharz; Pawel Stelmasiak; Karol Nietupski; Katarzyna Ossolinska-Skurczynska; Michal Sobieszczuk; Tomasz Demkow; Pawel Wiechno Journal: Med Oncol Date: 2019-11-25 Impact factor: 3.064
Authors: Reza Mehrazin; Zachary Piotrowski; Brian Egleston; Daniel Parker; Jeffrey J Tomaszweski; Marc C Smaldone; Philip H Abbosh; Timothy Ito; Paul Bloch; Kevan Iffrig; Marijo Bilusic; David Y T Chen; Rosalia Viterbo; Richard E Greenberg; Robert G Uzzo; Alexander Kutikov Journal: Urology Date: 2014-10-24 Impact factor: 2.649
Authors: Mieke Van Hemelrijck; Jan Adolfsson; Hans Garmo; Anna Bill-Axelson; Ola Bratt; Erik Ingelsson; Mats Lambe; Pär Stattin; Lars Holmberg Journal: Lancet Oncol Date: 2010-04-13 Impact factor: 41.316
Authors: Aaron Weinberg; Jason Wright; Christopher Deibert; Yu-Shiang Lu; Dawn Hershman; Alfred Neugut; Benjamin Spencer Journal: World J Urol Date: 2013-11-29 Impact factor: 4.226